6 results on '"Bangdiwala, Ananta"'
Search Results
2. Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic.
- Author
-
Pullen, Matthew F, Pastick, Katelyn A, Williams, Darlisha A, Nascene, Alanna A, Bangdiwala, Ananta S, Okafor, Elizabeth C, Hullsiek, Katherine Huppler, Skipper, Caleb P, Lofgren, Sarah M, Engen, Nicole, Abassi, Mahsa, McDonald, Emily G, Lee, Todd C, Rajasingham, Radha, and Boulware, David R
- Subjects
CLINICAL trials ,COVID-19 pandemic ,PANDEMICS ,EXPERIMENTAL design ,DISEASE prevalence ,HEALTH care reminder systems - Abstract
As the severe acute respiratory syndrome coronavirus 2 pandemic evolved, it was apparent that well designed and rapidly conducted randomized clinical trials were urgently needed. However, traditional clinical trial design presented several challenges. Notably, disease prevalence initially varied by time and region, and the pockets of outbreaks evolved geographically over time. Coupled with an occupational hazard from in-person study visits, timely recruitment would prove difficult in a traditional in-person clinical trial. Thus, our team opted to launch nationwide internet-based clinical trials using patient-reported outcome measures. In total, 2795 participants were recruited using traditional and social media, with screening and enrollment performed via an online data capture system. Follow-up surveys and survey reminders were similarly managed through this online system with manual participant outreach in the event of missing data. In this report, we present a narrative of our experience running internet-based clinical trials and provide recommendations for the design of future clinical trials during a world pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.
- Author
-
Lofgren, Sarah M, Nicol, Melanie R, Bangdiwala, Ananta S, Pastick, Katelyn A, Okafor, Elizabeth C, Skipper, Caleb P, Pullen, Matthew F, Engen, Nicole W, Abassi, Mahsa, Williams, Darlisha A, Nascene, Alanna A, Axelrod, Margaret L, Lother, Sylvain A, MacKenzie, Lauren J, Drobot, Glen, Marten, Nicole, Cheng, Matthew P, Zarychanski, Ryan, Schwartz, Ilan S, and Silverman, Michael
- Subjects
DRUG side effects ,COVID-19 ,HYDROXYCHLOROQUINE ,COVID-19 treatment ,ATRIAL arrhythmias ,CLINICAL trials - Abstract
Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease 2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from 3 outpatient randomized clinical trials. Methods We conducted 3 randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, postexposure prophylaxis, and early treatment for COVID-19 using an internet-based design. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. Results We enrolled 2795 participants. The median age of research participants (interquartile range) was 40 (34–49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2544 (91%) participants reported side effect data, and 748 (29%) reported at least 1 medication side effect. Side effects were reported in 40% with once-daily, 36% with twice-weekly, 31% with once-weekly hydroxychloroquine, compared with 19% with placebo. The most common side effects were upset stomach or nausea (25% with once-daily, 19% with twice-weekly, and 18% with once-weekly hydroxychloroquine, vs 11% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for once-daily, 17% twice-weekly, and 13% once-weekly hydroxychloroquine, vs 7% for placebo). Two individuals were hospitalized for atrial arrhythmias, 1 on placebo and 1 on twice-weekly hydroxychloroquine. No sudden deaths occurred. Conclusions Data from 3 outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials, in cohorts of healthy outpatients, can safely investigate whether hydroxychloroquine is efficacious for COVID-19. ClinicalTrials.gov Identifier NCT04308668 for postexposure prophylaxis and early treatment trials; NCT04328467 for pre-exposure prophylaxis trial. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.
- Author
-
Pullen, Matthew F, Hullsiek, Katherine Huppler, Rhein, Joshua, Musubire, Abdu K, Tugume, Lillian, Nuwagira, Edwin, Abassi, Mahsa, Ssebambulidde, Kenneth, Mpoza, Edward, Kiggundu, Ruben, Akampurira, Andrew, Nabeta, Henry W, Schutz, Charlotte, Evans, Emily E, Rajasingham, Radha, Skipper, Caleb P, Pastick, Katelyn A, Williams, Darlisha A, Morawski, Bozena M, and Bangdiwala, Ananta S
- Subjects
CEREBROSPINAL fluid examination ,AMPHOTERICIN B ,ANTIFUNGAL agents ,CLINICAL trials ,CRYPTOCOCCUS neoformans ,CULTURES (Biology) ,FUNGI ,MENINGITIS ,REGRESSION analysis ,SURVIVAL ,SECONDARY analysis ,PROPORTIONAL hazards models ,DESCRIPTIVE statistics ,FLUCONAZOLE ,COLONY-forming units assay ,PHARMACODYNAMICS - Abstract
Background In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint for all-cause mortality. The Food and Drug Administration allows for using surrogate endpoints for accelerated regulatory approval, but EFA as a surrogate endpoint requires further validation. We examined the relationship between rate of CSF Cryptococcus clearance (EFA) and mortality through 18 weeks. Methods We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during 2010–2017. All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitative CSF cultures. The log
10 -transformed colony-forming units (CFUs) per mL CSF were analyzed by general linear regression versus day of culture over the first 10 days. Results Mortality through 18 weeks was 37% for EFA > = 0.60 (n = 170), 36% for 0.40–0.59 (n = 182), 39% for 0.30–0.39 (n = 112), 35% for 0.20–0.29 (n = 87), and 50% for those with EFA < 0.20 CFU/mL/day (n = 187). The hazard ratio for 18-week mortality, comparing those with EFA < 0.20 to those with EFA > = 0.20, was 1.60 (95% confidence interval, 1.25, 2.04; P = .002). The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients with CSF pleocytosis (P < .001). Conclusions EFA is associated with all-cause mortality in cryptococcal meningitis. An EFA threshold of > = 0.20 log10 CFU/mL/day was associated with similar 18-week mortality (37%) compared to 50% mortality with EFA < 0.20. This EFA threshold may be considered a target for a surrogate endpoint. This builds upon existing studies to validate EFA as a surrogate endpoint. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Symptoms of COVID-19 Outpatients in the United States.
- Author
-
Pullen, Matthew F, Skipper, Caleb P, Hullsiek, Kathy H, Bangdiwala, Ananta S, Pastick, Katelyn A, Okafor, Elizabeth C, Lofgren, Sarah M, Rajasingham, Radha, Engen, Nicole W, Galdys, Alison, Williams, Darlisha A, Abassi, Mahsa, and Boulware, David R
- Subjects
SYMPTOMS ,COVID-19 ,SARS-CoV-2 ,CLINICAL trials ,OUTPATIENTS - Abstract
Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due to insufficient diagnostic testing in the United States, there is a need for clinical decision-making algorithms to guide testing prioritization. Methods We recruited participants nationwide for a randomized clinical trial. We categorized participants into 3 groups: (1) those with confirmed SARS-CoV-2 infection, (2) those with probable SARS-CoV-2 infection (pending test or not tested but with a confirmed COVID-19 contact), and (3) those with possible SARS-CoV-2 infection (pending test or not tested and with a contact for whom testing was pending or not performed). We compared the frequency of self-reported symptoms in each group and categorized those reporting symptoms in early infection (0–2 days), midinfection (3–5 days), and late infection (>5 days). Results Among 1252 symptomatic persons screened, 316 had confirmed, 393 had probable, and 543 had possible SARS-CoV-2 infection. In early infection, those with confirmed and probable SARS-CoV-2 infection shared similar symptom profiles, with fever most likely in confirmed cases (P = .002). Confirmed cases did not show any statistically significant differences compared with unconfirmed cases in symptom frequency at any time point. The most commonly reported symptoms in those with confirmed infection were cough (82%), fever (67%), fatigue (62%), and headache (60%), with only 52% reporting both fever and cough. Conclusions Symptomatic persons with probable SARS-CoV-2 infection present similarly to those with confirmed SARS-CoV-2 infection. There was no pattern of symptom frequency over time. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Technical procedures and REDCap tools for internet-based clinical trials.
- Author
-
Bangdiwala, Ananta S. and Boulware, David R.
- Subjects
- *
COVID-19 , *CORONAVIRUS disease treatment , *CLINICAL trials , *DATABASE management - Abstract
In March of 2020 our team of researchers developed and opened three clinical trials to investigate hydroxychloroquine as prophylaxis or treatment for the coronavirus disease 2019 (COVID-19). We simultaneously built corresponding Research Electronic Data Capture (REDCap) projects for these low-touch, remote trials that relied on participant-reported data. REDCap has built-in features that support pragmatic, internet-based studies, and REDCap is flexible enough to allow creative solutions for specific trials. We describe challenges, choices, and suggestions based on our experience with REDCap for our COVID-19 trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.